project id: TCGA-CESC; case submitter id: TCGA-VS-A9V1; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wgs: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.86; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.18; rna integrity number: 7.8; age at index: 46; days to birth: -17001; days to death: 157; ethnicity: not reported; gender: female; race: white; vital status: Dead; year of birth: 1967; year of death: 2013; age at diagnosis: 17001; ajcc pathologic m: MX; ajcc pathologic n: NX; ajcc pathologic t: T3b; classification of tumor: not reported; days to diagnosis: 0; figo stage: Stage IVB; icd 10 code: C53.9; last known disease status: not reported; morphology: 8482/3; primary diagnosis: Mucinous adenocarcinoma, endocervical type; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Cervix uteri; synchronous malignancy: No; tissue or organ of origin: Cervix uteri; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: yes; alcohol history: Not Reported; cigarettes per day: 0.13150684931506848; pack years smoked: 2.4; is ffpe: false; composition: Not Reported; days to collection: 217; days to sample procurement: 0; initial weight: 60.0; portion submitter id: TCGA-VS-A9V1-01A-11; percent lymphocyte infiltration: 10.0; percent monocyte infiltration: 1.0; percent necrosis: 0.0; percent neutrophil infiltration: 1.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 100.0; percent tumor nuclei: 60.0;